Back
Compare AU
Compare ETPMAG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are ETPMAG and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
ETPMAG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 775 | 69 |
Median incremental investment | $1,480.25 | $673.61 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,936.00 | $1,989.89 |
Average age group | > 35 | > 35 |
Key Summary
ETPMAG | CURE | |
|---|---|---|
Strategy | ETPMAG.AX was created on 2009-01-02 by Global X. The fund's investment portfolio concentrates primarily on silver commodities. ETFS Physical Silver (ETPMAG.AX) is designed to offer investors a simple, costefficient and secure way to access physical silver by providing a return equivalent to the movements in the silver spot price less the applicable management fee. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Global X Metal Securities Australia Limited (100 %) | Travere Therapeutics Inc Ordinary Shares (1.73 %) TG Therapeutics Inc (1.71 %) Alkermes PLC (1.62 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | |
Management fee | 0.49 % | 0.45 % |
Key Summary
ETPMAG | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | LBMA Silver Spot Price AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.49 % | 0.45 % |
Price | $96.80 | $64.19 |
Size | $1.571 billion | $41.191 million |
10Y return | 350.86 % | N/A |
Annual dividend/ distribution yield (5Y) | - % | 5.08 % |
Market | ASX | ASX |
First listed date | 30/01/2009 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ETPMAG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 775 | 69 |
Median incremental investment | $1,480.25 | $673.61 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,936.00 | $1,989.89 |
Average age group | > 35 | > 35 |
Pros and Cons
ETPMAG | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ETPMAG | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |